Aerie Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Aerie Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).

32 total trials none currently recruiting 32 completed early-phase tilt top decile by trial count

Aerie Pharmaceuticals: 32 sponsored US clinical trials, none currently recruiting.

Aerie Pharmaceuticals sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 11 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 2 trials.

Top-decile sponsor footprint

Aerie Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

32 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

32 total, page 1 of 1

COMPLETED Phase 3

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111
COMPLETED Phase 3

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966
COMPLETED Phase 3

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644
COMPLETED Phase 4

Rocklatan® Evaluation

NCT05283395
COMPLETED Phase 1

Study Evaluating Techniques for Measuring Tear Production

NCT05497479
COMPLETED Phase 2

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT04498182
COMPLETED Phase 2

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

NCT04498169
COMPLETED Phase 1

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

NCT03835884
COMPLETED Phase 2

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
COMPLETED Phase 4

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
COMPLETED Phase 2

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
COMPLETED Phase 2

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308
COMPLETED Phase 2

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846
COMPLETED Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
COMPLETED Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400
COMPLETED Phase 3

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
COMPLETED Phase 1

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

NCT02406287
COMPLETED Phase 3

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
COMPLETED Phase 3

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
COMPLETED Phase 3

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
COMPLETED Phase 2

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575
COMPLETED Phase 1

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

NCT01997879
COMPLETED Phase 2

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736
COMPLETED Phase 2

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002
COMPLETED Phase 2

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787
COMPLETED Phase 2

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

NCT01474135
COMPLETED Phase 2

24-hour Efficacy of AR-12286

NCT01330979
COMPLETED Phase 2

AR-12286 in Combination With Latanoprost

NCT01302249
COMPLETED Phase 1

Formulation Comparison in Normal Volunteers

NCT01250197
COMPLETED Phase 2

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579
COMPLETED Phase 2

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
COMPLETED Phase 2

Ocular Hypotensive Efficacy of AR-102

NCT00523250

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 16
Phase 3 9
Phase 4 2

Therapeutic Areas

Dry Eye Disease 2
Primary Open Angle Glaucoma or Ocular Hypertension 2
Open Angle Glaucoma 2
Ocular Hypertension 2
Corneal Edema 1
Normal Volunteers 1
Healthy 1

How the Aerie Pharmaceuticals early-phase archive is shaped

32 indexed studies, none listed as recruiting (0% open); 32 completed (100%).

Phase mix: 11 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Dry Eye Disease (2 trials), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aerie Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 010203040 0%5%10%15%20% Total trials Recruiting share Aerie PharmaceuticalsAllina Health SystemArdea BiosciencesHebrew SeniorLifeMiMedx Group10xBio22nd Century Group23andMe3-C Institute for Social Development
Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aerie Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 32 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aerie Pharmaceuticals page

32 registered trials is a research-attention snapshot, not an endorsement of Aerie Pharmaceuticals or any single study.

  • None of Aerie Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dry Eye Disease is the condition Aerie Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aerie Pharmaceuticals pipeline card: 32 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.